NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
10
LABU Quote, Financials, Valuation and Earnings
Last price:
$94.89
Seasonality move
:
-9.57%
Day range:
$88.40 - $96.11
52-week range:
$80.41 - $176.99
Dividend yield:
0.6%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.3M
Avg. volume:
1.3M
1-year change:
-4.18%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LABU
Direxion Daily S&P Biotech Bull 3X Shares
|
-- | -- | -- | -- | -- |
|
DPST
Direxion Daily Regional Banks Bull 3X Shares
|
-- | -- | -- | -- | -- |
|
ROM
ProShares Ultra Technology
|
-- | -- | -- | -- | -- |
|
UDOW
ProShares UltraPro Dow30
|
-- | -- | -- | -- | -- |
|
UYG
ProShares Ultra Financials
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LABU
Direxion Daily S&P Biotech Bull 3X Shares
|
$94.24 | -- | -- | -- | $0.15 | 0.6% | -- |
|
DPST
Direxion Daily Regional Banks Bull 3X Shares
|
$110.53 | -- | -- | -- | $0.49 | 1.75% | -- |
|
ROM
ProShares Ultra Technology
|
$71.67 | -- | -- | -- | $0.06 | 0.16% | -- |
|
UDOW
ProShares UltraPro Dow30
|
$97.13 | -- | -- | -- | $0.31 | 0.92% | -- |
|
UYG
ProShares Ultra Financials
|
$85.65 | -- | -- | -- | $0.09 | 0.45% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$91.28 | -- | -- | -- | $0.02 | 0.16% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LABU
Direxion Daily S&P Biotech Bull 3X Shares
|
-- | 5.522 | -- | -- |
|
DPST
Direxion Daily Regional Banks Bull 3X Shares
|
-- | 3.370 | -- | -- |
|
ROM
ProShares Ultra Technology
|
-- | 2.473 | -- | -- |
|
UDOW
ProShares UltraPro Dow30
|
-- | 2.749 | -- | -- |
|
UYG
ProShares Ultra Financials
|
-- | 1.709 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 2.133 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LABU
Direxion Daily S&P Biotech Bull 3X Shares
|
-- | -- | -- | -- | -- | -- |
|
DPST
Direxion Daily Regional Banks Bull 3X Shares
|
-- | -- | -- | -- | -- | -- |
|
ROM
ProShares Ultra Technology
|
-- | -- | -- | -- | -- | -- |
|
UDOW
ProShares UltraPro Dow30
|
-- | -- | -- | -- | -- | -- |
|
UYG
ProShares Ultra Financials
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
Direxion Daily S&P Biotech Bull 3X Shares vs. Competitors
-
Which has Higher Returns LABU or DPST?
Direxion Daily Regional Banks Bull 3X Shares has a net margin of -- compared to Direxion Daily S&P Biotech Bull 3X Shares's net margin of --. Direxion Daily S&P Biotech Bull 3X Shares's return on equity of -- beat Direxion Daily Regional Banks Bull 3X Shares's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- DPSTDirexion Daily Regional Banks Bull 3X Shares-- -- -- -
What do Analysts Say About LABU or DPST?
Direxion Daily S&P Biotech Bull 3X Shares has a consensus price target of --, signalling downside risk potential of --. On the other hand Direxion Daily Regional Banks Bull 3X Shares has an analysts' consensus of -- which suggests that it could fall by --. Given that Direxion Daily S&P Biotech Bull 3X Shares has higher upside potential than Direxion Daily Regional Banks Bull 3X Shares, analysts believe Direxion Daily S&P Biotech Bull 3X Shares is more attractive than Direxion Daily Regional Banks Bull 3X Shares.
Company Buy Ratings Hold Ratings Sell Ratings LABUDirexion Daily S&P Biotech Bull 3X Shares0 0 0 DPSTDirexion Daily Regional Banks Bull 3X Shares0 0 0 -
Is LABU or DPST More Risky?
Direxion Daily S&P Biotech Bull 3X Shares has a beta of 2.860, which suggesting that the stock is 186.014% more volatile than S&P 500. In comparison Direxion Daily Regional Banks Bull 3X Shares has a beta of 2.939, suggesting its more volatile than the S&P 500 by 193.87%.
-
Which is a Better Dividend Stock LABU or DPST?
Direxion Daily S&P Biotech Bull 3X Shares has a quarterly dividend of $0.15 per share corresponding to a yield of 0.6%. Direxion Daily Regional Banks Bull 3X Shares offers a yield of 1.75% to investors and pays a quarterly dividend of $0.49 per share. Direxion Daily S&P Biotech Bull 3X Shares pays -- of its earnings as a dividend. Direxion Daily Regional Banks Bull 3X Shares pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LABU or DPST?
Direxion Daily S&P Biotech Bull 3X Shares quarterly revenues are --, which are smaller than Direxion Daily Regional Banks Bull 3X Shares quarterly revenues of --. Direxion Daily S&P Biotech Bull 3X Shares's net income of -- is lower than Direxion Daily Regional Banks Bull 3X Shares's net income of --. Notably, Direxion Daily S&P Biotech Bull 3X Shares's price-to-earnings ratio is -- while Direxion Daily Regional Banks Bull 3X Shares's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Direxion Daily S&P Biotech Bull 3X Shares is -- versus -- for Direxion Daily Regional Banks Bull 3X Shares. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- -- DPSTDirexion Daily Regional Banks Bull 3X Shares-- -- -- --
-
Which has Higher Returns LABU or ROM?
ProShares Ultra Technology has a net margin of -- compared to Direxion Daily S&P Biotech Bull 3X Shares's net margin of --. Direxion Daily S&P Biotech Bull 3X Shares's return on equity of -- beat ProShares Ultra Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- ROMProShares Ultra Technology-- -- -- -
What do Analysts Say About LABU or ROM?
Direxion Daily S&P Biotech Bull 3X Shares has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Direxion Daily S&P Biotech Bull 3X Shares has higher upside potential than ProShares Ultra Technology, analysts believe Direxion Daily S&P Biotech Bull 3X Shares is more attractive than ProShares Ultra Technology.
Company Buy Ratings Hold Ratings Sell Ratings LABUDirexion Daily S&P Biotech Bull 3X Shares0 0 0 ROMProShares Ultra Technology0 0 0 -
Is LABU or ROM More Risky?
Direxion Daily S&P Biotech Bull 3X Shares has a beta of 2.860, which suggesting that the stock is 186.014% more volatile than S&P 500. In comparison ProShares Ultra Technology has a beta of 2.327, suggesting its more volatile than the S&P 500 by 132.701%.
-
Which is a Better Dividend Stock LABU or ROM?
Direxion Daily S&P Biotech Bull 3X Shares has a quarterly dividend of $0.15 per share corresponding to a yield of 0.6%. ProShares Ultra Technology offers a yield of 0.16% to investors and pays a quarterly dividend of $0.06 per share. Direxion Daily S&P Biotech Bull 3X Shares pays -- of its earnings as a dividend. ProShares Ultra Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LABU or ROM?
Direxion Daily S&P Biotech Bull 3X Shares quarterly revenues are --, which are smaller than ProShares Ultra Technology quarterly revenues of --. Direxion Daily S&P Biotech Bull 3X Shares's net income of -- is lower than ProShares Ultra Technology's net income of --. Notably, Direxion Daily S&P Biotech Bull 3X Shares's price-to-earnings ratio is -- while ProShares Ultra Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Direxion Daily S&P Biotech Bull 3X Shares is -- versus -- for ProShares Ultra Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- -- ROMProShares Ultra Technology-- -- -- --
-
Which has Higher Returns LABU or UDOW?
ProShares UltraPro Dow30 has a net margin of -- compared to Direxion Daily S&P Biotech Bull 3X Shares's net margin of --. Direxion Daily S&P Biotech Bull 3X Shares's return on equity of -- beat ProShares UltraPro Dow30's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- UDOWProShares UltraPro Dow30-- -- -- -
What do Analysts Say About LABU or UDOW?
Direxion Daily S&P Biotech Bull 3X Shares has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares UltraPro Dow30 has an analysts' consensus of -- which suggests that it could fall by --. Given that Direxion Daily S&P Biotech Bull 3X Shares has higher upside potential than ProShares UltraPro Dow30, analysts believe Direxion Daily S&P Biotech Bull 3X Shares is more attractive than ProShares UltraPro Dow30.
Company Buy Ratings Hold Ratings Sell Ratings LABUDirexion Daily S&P Biotech Bull 3X Shares0 0 0 UDOWProShares UltraPro Dow300 0 0 -
Is LABU or UDOW More Risky?
Direxion Daily S&P Biotech Bull 3X Shares has a beta of 2.860, which suggesting that the stock is 186.014% more volatile than S&P 500. In comparison ProShares UltraPro Dow30 has a beta of 2.907, suggesting its more volatile than the S&P 500 by 190.706%.
-
Which is a Better Dividend Stock LABU or UDOW?
Direxion Daily S&P Biotech Bull 3X Shares has a quarterly dividend of $0.15 per share corresponding to a yield of 0.6%. ProShares UltraPro Dow30 offers a yield of 0.92% to investors and pays a quarterly dividend of $0.31 per share. Direxion Daily S&P Biotech Bull 3X Shares pays -- of its earnings as a dividend. ProShares UltraPro Dow30 pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LABU or UDOW?
Direxion Daily S&P Biotech Bull 3X Shares quarterly revenues are --, which are smaller than ProShares UltraPro Dow30 quarterly revenues of --. Direxion Daily S&P Biotech Bull 3X Shares's net income of -- is lower than ProShares UltraPro Dow30's net income of --. Notably, Direxion Daily S&P Biotech Bull 3X Shares's price-to-earnings ratio is -- while ProShares UltraPro Dow30's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Direxion Daily S&P Biotech Bull 3X Shares is -- versus -- for ProShares UltraPro Dow30. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- -- UDOWProShares UltraPro Dow30-- -- -- --
-
Which has Higher Returns LABU or UYG?
ProShares Ultra Financials has a net margin of -- compared to Direxion Daily S&P Biotech Bull 3X Shares's net margin of --. Direxion Daily S&P Biotech Bull 3X Shares's return on equity of -- beat ProShares Ultra Financials's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- UYGProShares Ultra Financials-- -- -- -
What do Analysts Say About LABU or UYG?
Direxion Daily S&P Biotech Bull 3X Shares has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Financials has an analysts' consensus of -- which suggests that it could fall by --. Given that Direxion Daily S&P Biotech Bull 3X Shares has higher upside potential than ProShares Ultra Financials, analysts believe Direxion Daily S&P Biotech Bull 3X Shares is more attractive than ProShares Ultra Financials.
Company Buy Ratings Hold Ratings Sell Ratings LABUDirexion Daily S&P Biotech Bull 3X Shares0 0 0 UYGProShares Ultra Financials0 0 0 -
Is LABU or UYG More Risky?
Direxion Daily S&P Biotech Bull 3X Shares has a beta of 2.860, which suggesting that the stock is 186.014% more volatile than S&P 500. In comparison ProShares Ultra Financials has a beta of 2.124, suggesting its more volatile than the S&P 500 by 112.388%.
-
Which is a Better Dividend Stock LABU or UYG?
Direxion Daily S&P Biotech Bull 3X Shares has a quarterly dividend of $0.15 per share corresponding to a yield of 0.6%. ProShares Ultra Financials offers a yield of 0.45% to investors and pays a quarterly dividend of $0.09 per share. Direxion Daily S&P Biotech Bull 3X Shares pays -- of its earnings as a dividend. ProShares Ultra Financials pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LABU or UYG?
Direxion Daily S&P Biotech Bull 3X Shares quarterly revenues are --, which are smaller than ProShares Ultra Financials quarterly revenues of --. Direxion Daily S&P Biotech Bull 3X Shares's net income of -- is lower than ProShares Ultra Financials's net income of --. Notably, Direxion Daily S&P Biotech Bull 3X Shares's price-to-earnings ratio is -- while ProShares Ultra Financials's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Direxion Daily S&P Biotech Bull 3X Shares is -- versus -- for ProShares Ultra Financials. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- -- UYGProShares Ultra Financials-- -- -- --
-
Which has Higher Returns LABU or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to Direxion Daily S&P Biotech Bull 3X Shares's net margin of --. Direxion Daily S&P Biotech Bull 3X Shares's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About LABU or XBI?
Direxion Daily S&P Biotech Bull 3X Shares has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Direxion Daily S&P Biotech Bull 3X Shares has higher upside potential than SPDR S&P Biotech ETF, analysts believe Direxion Daily S&P Biotech Bull 3X Shares is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings LABUDirexion Daily S&P Biotech Bull 3X Shares0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is LABU or XBI More Risky?
Direxion Daily S&P Biotech Bull 3X Shares has a beta of 2.860, which suggesting that the stock is 186.014% more volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.956, suggesting its less volatile than the S&P 500 by 4.394%.
-
Which is a Better Dividend Stock LABU or XBI?
Direxion Daily S&P Biotech Bull 3X Shares has a quarterly dividend of $0.15 per share corresponding to a yield of 0.6%. SPDR S&P Biotech ETF offers a yield of 0.16% to investors and pays a quarterly dividend of $0.02 per share. Direxion Daily S&P Biotech Bull 3X Shares pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LABU or XBI?
Direxion Daily S&P Biotech Bull 3X Shares quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. Direxion Daily S&P Biotech Bull 3X Shares's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, Direxion Daily S&P Biotech Bull 3X Shares's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Direxion Daily S&P Biotech Bull 3X Shares is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 6.33% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 14.95% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.81% over the past day.
